Nelmastobart in Combination With Tas-102 and Bevacizumab in Recurrent/Metastatic Colorectal Cancer

NCT07656038 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Colonrectal Cancer (CRC)

Interventions

DRUG: Nelmastobart in combination with TAS-102 and Bevacizumab

Sponsor

STCube, Inc.